Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Adoptive Therapy With Chimeric Antigen Receptor–Modified T Cells of Defined Subset Composition

1 Mar 2014

Abstract excerpt

The ability to engineer T cells to recognize tumor cells through genetic modification with a synthetic chimeric antigen receptor has ushered in a new era in cancer immunotherapy. The most advanced clinical applications are in targeting CD19 on B-cell malignancies. The clinical trials of CD19 chimeric antigen receptor therapy have thus far not attempted to select defined subsets before transduction or imposed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to CRISPR and Genetic Engineering
Share to Nanowire Synthesis and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24667960
DOI: 10.1097/ppo.0000000000000036

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Adoptive Therapy With Chimeric Antigen Receptor–Modified T Cells of Defined Subset CompositionPMID 24667960Read ↗

Design and implementation of adoptive therapy with chimeric antigen receptor‐modified T cellsSemantic proximity Read ↗

CAR therapy: the CD19 paradigmSemantic proximity Read ↗

First generation anti-CD19 chimeric antigen receptor-modified T cells for management of B cell malignances: initial analysis of an ongoing Phase I clinical trialSemantic proximity Read ↗

Fully human CD19-specific chimeric antigen receptors for T-cell therapySemantic proximity Read ↗

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCRSemantic proximity Read ↗

Chimeric antigen receptor-modified T cells strike backSemantic proximity Read ↗

Future perspectives on novel CAR-T therapeutics beyond CD19 and BCMA in onco-hematologySemantic proximity Read ↗

Immunogenicity of CAR T cells in cancer therapy.Semantic proximity Read ↗

Chimeric Antigen Receptors Modified T-Cells for Cancer TherapySemantic proximity Read ↗

Chimeric Antigen Receptors: A Paradigm Shift in ImmunotherapySemantic proximity Read ↗

Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignanciesSemantic proximity Read ↗

Novel Approaches to Enhance the Specificity and Safety of Engineered T CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.